1 August 2017

Verona Pharma to Present at 2017 Wedbush PacGrow Healthcare Conference

LONDON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the 2017 Wedbush PacGrow Healthcare Conference.

An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com.  A replay of the webcast will be made available for 90 days following the presentation.

Event: Wedbush PacGrow Healthcare Conference
Date: August 15, 2017
Time: 3:05 PM EDT
Location: New York, NY

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma.

For further information, please contact:

Verona Pharma plc       Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer       info@veronapharma.com
         
N+1 Singer (Nominated Adviser and UK Broker)       Tel: +44 (0)20 7496 3000
Aubrey Powell / James White        
         
FTI Consulting (UK Media and Investor enquiries)       Tel: +44 (0)20 3727 1000
Simon Conway / Stephanie Cuthbert /
Natalie Garland-Collins
      veronapharma@fticonsulting.com
         
ICR, Inc. (US Media and Investor enquiries)        
James Heins       Tel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie Carrington       Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com

 

Primary Logo

 

Verona Pharma plc

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us